Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Novel Association of RAD54L Mutation with Müllerian Clear Cell Carcinoma of the Male Urethra: New Insights Regarding the Molecular Mechanisms of a Rare Tumour

Author(s): Huiyan Deng, Yan Ding, Zhiyu Wang, Xiangdong Liang and Yueping Liu*

Volume 24, Issue 10, 2024

Published on: 25 January, 2024

Page: [1080 - 1087] Pages: 8

DOI: 10.2174/0115680096260943231212043820

Price: $65

Abstract

Introduction: Müllerian clear cell carcinoma of the male urethra is similar to that of the female genital tract in terms of morphology and immunohistochemical expression but is rarely observed in clinical practice.

Case Presentation: Here, we report the case of a 65-year-old man diagnosed with Müllerian clear cell carcinoma who harboured a mutation in RAD54L. This patient was diagnosed by electrocautery and ultimately underwent prostatectomy. After a six-month follow-up period, no signs of recurrence or additional malignancy were found. Based on our analysis of the available literature, it appears that Müllerian clear cell carcinoma with RAD54L mutation has not been reported until now.

Conclusion: This case enhances our knowledge of the molecular biology of Müllerian clear cell carcinoma of the male urethra, which will help clinicians select optimal treatment options for this rare cancer in patients with specific driver mutations.

« Previous
Graphical Abstract

[1]
Hogen, L.; Thomas, G.; Bernardini, M.; Bassiouny, D.; Brar, H.; Gien, L.T.; Rosen, B.; Le, L.; Vicus, D. The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma. Gynecol. Oncol., 2016, 143(2), 258-263.
[http://dx.doi.org/10.1016/j.ygyno.2016.09.006] [PMID: 27623251]
[2]
Chan, J.K.; Teoh, D.; Hu, J.M.; Shin, J.Y.; Osann, K.; Kapp, D.S. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol. Oncol., 2008, 109(3), 370-376.
[http://dx.doi.org/10.1016/j.ygyno.2008.02.006] [PMID: 18395777]
[3]
Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; Burger, R.A.; Mannel, R.S.; DeGeest, K.; Hartenbach, E.M.; Baergen, R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol., 2003, 21(17), 3194-3200.
[http://dx.doi.org/10.1200/JCO.2003.02.153] [PMID: 12860964]
[4]
Matsuzaki, S.; Yoshino, K.; Ueda, Y.; Matsuzaki, S.; Kakuda, M.; Okazawa, A.; Egawa-Takata, T.; Kobayashi, E.; Kimura, T. Potential targets for ovarian clear cell carcinoma: A review of updates and future perspectives. Cancer Cell Int., 2015, 15(1), 117.
[http://dx.doi.org/10.1186/s12935-015-0267-0] [PMID: 26675567]
[5]
Ye, H.; Wang, K.; Wang, M.; Liu, R.; Song, H.; Li, N.; Lu, Q.; Zhang, W.; Du, Y.; Yang, W.; Zhong, L.; Wang, Y.; Yu, B.; Wang, H.; Kan, Q.; Zhang, H.; Wang, Y.; He, Z.; Sun, J. Bioinspired nanoplatelets for chemo-photothermal therapy of breast cancer metastasis inhibition. Biomaterials, 2019, 206, 1-12.
[http://dx.doi.org/10.1016/j.biomaterials.2019.03.024] [PMID: 30921730]
[6]
Mehra, R.; Vats, P.; Kalyana-Sundaram, S.; Udager, A.M.; Roh, M.; Alva, A.; Pan, J.; Lonigro, R.J.; Siddiqui, J.; Weizer, A.; Lee, C.; Cao, X.; Wu, Y.M.; Robinson, D.R.; Dhanasekaran, S.M.; Chinnaiyan, A.M. Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am. J. Pathol., 2014, 184(3), 584-591.
[http://dx.doi.org/10.1016/j.ajpath.2013.11.023] [PMID: 24389164]
[7]
WHO Classification of Female Genital Tumours, 5th ed; International Agency for Research on Cancer, 2020, pp. 65-67.
[8]
Cantrell, B.B.; Leifer, G.; Deklerk, D.P.; Eggleston, J.C. Papillary adenocarcinoma of the prostatic urethra with clear-cell appearance. Cancer, 1981, 48(12), 2661-2667.
[http://dx.doi.org/10.1002/1097-0142(19811215)48:12<2661::AID-CNCR2820481218>3.0.CO;2-A] [PMID: 7306922]
[9]
Sugimura, R.; Kawahara, T.; Noguchi, G.; Takamoto, D.; Izumi, K.; Miyoshi, Y.; Kishida, T.; Yao, M.; Tanabe, M.; Uemura, H. Clear cell adenocarcinoma of the prostatic urethra: A case report. IJU Case Rep., 2019, 2(1), 19-22.
[http://dx.doi.org/10.1002/iju5.12028] [PMID: 32743364]
[10]
Li, C-C.; Chang, C-W.; Yin, H-L. Primary clear cell adenocarcinoma of prostate: A diagnostic challenge. Urol. Ann, 2021, 13(4), 434-437.
[http://dx.doi.org/10.4103/UA.UA_187_20] [PMID: 34759659]
[11]
Warmann, S.W.; Vogel, M.; Wehrmann, M.; Scheel-Walter, H.G.; Artlich, A.; Pereira, P.L.; Fuchs, J. Giant Mullerian duct cyst with malignant transformation in 15-year-old boy Urology, 2006, 67, 424-e3–424.e6. .
[http://dx.doi.org/10.1016/j.urology.2005.09.009]
[12]
Messika-Zeitoun, L.; Gouédard, L.; Belville, C.; Dutertre, M.; Lins, L.; Imbeaud, S.; Hughes, I.A.; Picard, J.Y.; Josso, N.; di Clemente, N. Autosomal recessive segregation of a truncating mutation of anti-Müllerian type II receptor in a family affected by the persistent Müllerian duct syndrome contrasts with its dominant negative activity in vitro. J. Clin. Endocrinol. Metab., 2001, 86(9), 4390-4397.
[http://dx.doi.org/10.1210/jcem.86.9.7839] [PMID: 11549681]
[13]
Fadare, O.; Zhao, C.; Khabele, D.; Parkash, V.; Quick, C.M.; Gwin, K.; Desouki, M.M. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Pathology, 2015, 47(2), 105-111.
[http://dx.doi.org/10.1097/PAT.0000000000000223] [PMID: 25551297]
[14]
Baig, F.A.; Hamid, A.; Mirza, T.; Syed, S. Ductal and acinar adenocarcinoma of prostate: morphological and immunohistochemical characterization. Oman Med. J., 2015, 30(3), 162-166.
[http://dx.doi.org/10.5001/omj.2015.36] [PMID: 26171121]
[15]
Mai, K.T.; Bateman, J.; Djordjevic, B.; Flood, T.A.; Belanger, E.C. Clear cell urothelial carcinoma. Int. J. Surg. Pathol., 2017, 25(1), 18-25.
[http://dx.doi.org/10.1177/1066896916660195] [PMID: 27422469]
[16]
Bong, I.P.N.; Ng, C.C.; Othman, N.; Esa, E. Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma. Genes Genomics, 2022, 44(8), 957-966.
[http://dx.doi.org/10.1007/s13258-022-01272-7] [PMID: 35689754]
[17]
Avsar, T.; El-mouyhiddin, R.; Calis, S.; Yapicier, O.; Kilic, T. Association of mthfr, mtrr, and rad54l gene variations with meningioma and their correlation with the tumor’s histopathological characteristics in turkish cohort. Turk Neurosurg., 2021, 31(4), 587-593.
[http://dx.doi.org/10.5137/1019-5149.JTN.33347-20.2] [PMID: 34169999]
[18]
Yoshimura, Y.; Kurasawa, M.; Yorozu, K.; Puig, O.; Bordogna, W.; Harada, N. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation. Cancer Chemother. Pharmacol., 2016, 77(3), 623-628.
[http://dx.doi.org/10.1007/s00280-016-2977-y] [PMID: 26849637]
[19]
Carlsson, E.; Ranki, A.; Sipilä, L.; Karenko, L.; Abdel-Rahman, W.M.; Ovaska, K.; Siggberg, L.; Aapola, U.; Ässämäki, R.; Häyry, V.; Niiranen, K.; Helle, M.; Knuutila, S.; Hautaniemi, S.; Peltomäki, P.; Krohn, K. Potential role of a navigator gene NAV3 in colorectal cancer. Br. J. Cancer, 2012, 106(3), 517-524.
[http://dx.doi.org/10.1038/bjc.2011.553] [PMID: 22173670]
[20]
Li, H.; Yang, L.L.; Wu, C.C.; Xiao, Y.; Mao, L.; Chen, L.; Zhang, W.F.; Sun, Z.J. Expression and prognostic value of IFIT1 and IFITM3 in head and neck squamous cell carcinoma. Am. J. Clin. Pathol., 2020, 153(5), 618-629.
[http://dx.doi.org/10.1093/ajcp/aqz205] [PMID: 31977029]
[21]
Zhao, W.; Wang, Y.; Yue, X. SLC22A16 upregulation is an independent unfavorable prognostic indicator in gastric cancer. Future Oncol., 2018, 14(21), 2139-2148.
[http://dx.doi.org/10.2217/fon-2018-0207] [PMID: 29698084]
[22]
Wang, X.; Haswell, J.R.; Roberts, C.W.M. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin. Cancer Res., 2014, 20(1), 21-27.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0280] [PMID: 24122795]
[23]
Jelinic, P.; Mueller, J.J.; Olvera, N.; Dao, F.; Scott, S.N.; Shah, R.; Gao, J.; Schultz, N.; Gonen, M.; Soslow, R.A.; Berger, M.F.; Levine, D.A. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat. Genet., 2014, 46(5), 424-426.
[http://dx.doi.org/10.1038/ng.2922] [PMID: 24658004]
[24]
La Fleur, L.; Falk-Sörqvist, E.; Smeds, P.; Berglund, A.; Sundström, M.; Mattsson, J.S.M.; Brandén, E.; Koyi, H.; Isaksson, J.; Brunnström, H.; Nilsson, M.; Micke, P.; Moens, L.; Botling, J. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer, 2019, 130, 50-58.
[http://dx.doi.org/10.1016/j.lungcan.2019.01.003] [PMID: 30885352]
[25]
Kokorovic, A.; Westerman, M.E.; Krause, K.; Hernandez, M.; Brooks, N.; Dinney, C.P.N.; Kamat, A.M.; Navai, N. Revisiting an old conundrum: A systematic review and meta-analysis of intravesical therapy for treatment of urothelial carcinoma of the prostate. Bladder Cancer, 2021, 7(2), 243-252.
[http://dx.doi.org/10.3233/BLC-200404] [PMID: 34195319]
[26]
Bastide, C.; Bruyère, F.; Karsenty, G.; Guy, L.; Rozet, F. Hormonal treatment in prostate cancer. Prog. Urol., 2013, 23(15), 1246-1257.
[http://dx.doi.org/10.1016/j.purol.2013.08.325] [PMID: 24183083]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy